PCRX
Pacira BioSciences, Inc.
NASDAQ · USHealthcareDrug Manufacturers - Specialty & Generic
$25.35-1.02%
Price as of Jul 20, 2026
PCRX financials
Pacira BioSciences, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $726.4M | $701.0M | $675.0M | $666.8M |
| Cost of revenue | $149.7M | $170.4M | $184.7M | $199.3M |
| Gross profit | $576.7M | $530.5M | $490.3M | $467.5M |
| Operating expenses | $543.4M | $603.9M | $402.6M | $407.5M |
| Operating income | $33.3M | -$73.4M | $87.7M | $60.0M |
| Net income | $7.0M | -$99.6M | $42.0M | $15.9M |
| EBITDA | $122.5M | $29.1M | $154.6M | $140.4M |
| Basic EPS | $0.16 | $-2.15 | $0.91 | $0.35 |
| Diluted EPS | $0.16 | $-2.15 | $0.89 | $0.34 |
| Balance sheet | ||||
| Cash & equivalents | $158.5M | $276.8M | $153.3M | $104.1M |
| Total assets | $1.3B | $1.6B | $1.6B | $1.7B |
| Total liabilities | $571.8M | $775.2M | $704.3M | $906.2M |
| Stockholders’ equity | $693.1M | $778.3M | $870.1M | $775.0M |
| Total debt | $454.4M | $638.9M | $586.0M | $763.4M |
| Net debt | $295.8M | $362.1M | $432.7M | $659.3M |
| Cash flow | ||||
| Operating cash flow | $152.0M | $189.4M | $154.6M | $145.3M |
| Capital expenditure | -$15.3M | -$10.6M | -$15.2M | -$30.1M |
| Free cash flow | $136.7M | $178.8M | $139.5M | $115.2M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | -$148.3M | -$25.0M | -$106.0K | $0.00 |